Key highlights
- GPS achieved a 41% reduction in the risk of death compared to best available treatment
- Median overall survival reached 24.0 months for the GPS group versus 14.7 months for the control arm
- The trial met its primary endpoint with a hazard ratio of 0.59 and a p-value of 0.035
- Treatment was generally well tolerated with primarily mild to moderate adverse events reported
- Company plans to meet with the FDA to discuss the regulatory pathway for a BLA submission
Pivotal Trial Results
SELLAS Life Sciences has reached a pivotal milestone with the release of topline data from its REGAL Phase 3 trial. The study focused on patients with acute myeloid leukemia (AML) who had achieved a second or later complete remission but were ineligible for stem cell transplantation. By meeting the primary endpoint of overall survival, the trial demonstrated that galinpepimut-S (GPS) successfully reduced the risk of death by 41% compared to investigator-selected best available treatments. This result is particularly significant given the historically poor prognosis for patients in this specific clinical stage who have very limited maintenance therapy options.
Clinical Significance and Pipeline Validation
The success of the REGAL trial serves as a critical validation for the company’s WT1-targeted immunotherapeutic approach. GPS is designed to target the Wilms Tumor 1 protein, which is frequently overexpressed in AML and various other cancers. By providing a median overall survival of 24.0 months versus 14.7 months for the control group, the drug has established a new benchmark for maintenance monotherapy in high-risk AML populations. SELLAS is now preparing for a Biologics License Application (BLA) submission, marking its transition toward potential commercial-stage operations and long-term therapeutic deployment.
Strategic Commentary
“REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients with AML who have very limited options after achieving a second remission.”
Business and Financial Landscape
SELLAS currently trades on the NASDAQ under the ticker SLS with a market capitalization of approximately $1.52 billion. Recent market data shows the stock facing significant volatility, with a month-over-month price decline of 34.13% and a Relative Strength Index (RSI) of 32.6. While the positive Phase 3 results provide a fundamental catalyst, the company’s financial path remains tied to its ability to navigate the FDA’s regulatory requirements for BLA approval. Future capital requirements will likely be influenced by the scale of commercial preparations required for the potential launch of GPS.
Management commentary
“REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients with AML who have very limited options after achieving a second remission.”
| Share price | $7.47 |
|---|---|
| Market cap | $1.5B |
| 1-month price change | -34.13% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by SELLAS Life Sciences Group, Inc. announcing positive topline results from the Phase 3 REGAL trial.
Track SELLAS Life Sciences Group, Inc. live
Get the next SELLAS Life Sciences Group, Inc. SEC filing seconds after it lands.



